WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H561723
CAS#: 13951-70-7
Description: 16alpha-Hydroxyprednisolone is a major CYP3A-dependent metabolite of budesonide.
Hodoodo Cat#: H561723
Name: 16alpha-Hydroxyprednisolone
CAS#: 13951-70-7
Chemical Formula: C21H28O6
Exact Mass: 376.19
Molecular Weight: 376.440
Elemental Analysis: C, 67.00; H, 7.50; O, 25.50
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: 16alpha-Hydroxyprednisolone; 16alpha Hydroxyprednisolone; OH-PRED; OH PRED;
IUPAC/Chemical Name: (8S,9S,10R,11S,13S,14S,16R,17S)-11,16,17-Trihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one
InChi Key: SEKYBDYVXDAYPY-ILNISADRSA-N
InChi Code: InChI=1S/C21H28O6/c1-19-6-5-12(23)7-11(19)3-4-13-14-8-16(25)21(27,17(26)10-22)20(14,2)9-15(24)18(13)19/h5-7,13-16,18,22,24-25,27H,3-4,8-10H2,1-2H3/t13-,14-,15-,16+,18+,19-,20-,21-/m0/s1
SMILES Code: O=C1C=C[C@]2(C)[C@@]3([H])[C@@H](O)C[C@]4(C)[C@](C(CO)=O)(O)[C@H](O)C[C@@]4([H])[C@]3([H])CCC2=C1
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 376.44 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Barton AK, Heinemann H, Schenk I, Machnik M, Gehlen H. Influence of respiratory tract disease and mode of inhalation on detectability of budesonide in equine urine and plasma. Am J Vet Res. 2017 Feb;78(2):244-250. doi: 10.2460/ajvr.78.2.244. PubMed PMID: 28140635.
2: Gazzotti T, Barbarossa A, Zironi E, Roncada P, Pietra M, Pagliuca G. An LC-MS/MS method for the determination of budesonide and 16α-hydroxyprednisolone in dog plasma. MethodsX. 2016 Feb 24;3:139-43. doi: 10.1016/j.mex.2016.02.004. eCollection 2016. PubMed PMID: 27408833; PubMed Central PMCID: PMC4929248.
3: Dilger K, Halter J, Bertz H, Lopez-Lazaro L, Gratwohl A, Finke J. Pharmacokinetics and pharmacodynamic action of budesonide after buccal administration in healthy subjects and patients with oral chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2009 Mar;15(3):336-43. doi: 10.1016/j.bbmt.2008.12.001. PubMed PMID: 19203724.
4: Fitzgerald M, Evill L, Banz K, Carroll S, Rodger J. Mineralocorticoids restore quiescent morphology and reduce VEGF receptor expression in inflamed choroidal endothelial cells in vitro. Ophthalmic Res. 2009;41(1):44-52. doi: 10.1159/000164799. Epub 2008 Oct 22. PubMed PMID: 18946227.
5: Ferraboschi P, Bertacche V, Maccone I, Pini E, Ragonesi L, Venturini A, Stradi R. Estimation and characterisation of budesonide tablets impurities. J Pharm Biomed Anal. 2008 Jul 15;47(3):636-40. doi: 10.1016/j.jpba.2008.01.050. Epub 2008 Feb 16. PubMed PMID: 18367362.
6: Dilger K, Fux R, Röck D, Mörike K, Gleiter CH. Effect of high-dose metronidazole on pharmacokinetics of oral budesonide and vice versa: a double drug interaction study. J Clin Pharmacol. 2007 Dec;47(12):1532-9. PubMed PMID: 18048573.
7: Deventer K, Mikulcíková P, Van Hoecke H, Van Eenoo P, Delbeke FT. Detection of budesonide in human urine after inhalation by liquid chromatography-mass spectrometry. J Pharm Biomed Anal. 2006 Oct 11;42(4):474-9. Epub 2006 Jul 12. PubMed PMID: 16842962.
8: Dilger K, Denk A, Heeg MH, Beuers U. No relevant effect of ursodeoxycholic acid on cytochrome P450 3A metabolism in primary biliary cirrhosis. Hepatology. 2005 Mar;41(3):595-602. PubMed PMID: 15726657.
9: Wang Y, Tang Y, Moellmann H, Hochhaus G. Simultaneous quantification of budesonide and its two metabolites, 6beta-hydroxybudesonide and 16alpha-hydroxyprednisolone, in human plasma by liquid chromatography negative electrospray ionization tandem mass spectrometry. Biomed Chromatogr. 2003 Mar-Apr;17(2-3):158-64. PubMed PMID: 12717805.
10: Faarvang HJ, Lauritsen OS. The relative effects of cortisone and triamcinolone (9alpha-fluoro-16alpha-hydroxyprednisolone) on the urinary excretion of trsin inhibitor in man. Acta Endocrinol (Copenh). 1969 Jul;61(3):477-82. PubMed PMID: 5820058.
11: Fauve RM, Pierce-Chase CH. Comparative effects of corticosteroids on host resistance to infection in relation to chemical structure. J Exp Med. 1967 May 1;125(5):807-21. PubMed PMID: 4960741; PubMed Central PMCID: PMC2138213.
